Insights from Fc receptor biology: A route to improved antibody reagents

References

• Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010; 2:181 - 9; http://dx.doi.org/10.4161/mabs.2.2.11158; PMID: 20150767
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005 - 10; http://dx.doi.org/10.1073/pnas.0508123103; PMID: 16537476
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Damschroder MM, Leach W, Wu H, Dall’Acqua WF. Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol 2008; 45:1872 - 82; http://dx.doi.org/10.1016/j.molimm.2007.10.042; PMID: 18078997
   PubMed Web of Science ®Google Scholar
• Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, et al. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays. J Immunol Methods 2011; 365:132 - 41; http://dx.doi.org/10.1016/j.jim.2010.12.014; PMID: 21185301
   PubMed Web of Science ®Google Scholar
• Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 2010; 116:3004 - 12; http://dx.doi.org/10.1182/blood-2010-01-265280; PMID: 20616215
   PubMed Web of Science ®Google Scholar
• An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, et al. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs 2009; 1:572 - 9; http://dx.doi.org/10.4161/mabs.1.6.10185; PMID: 20073128
   PubMed Web of Science ®Google Scholar
• Kaufman A, Herold KC. Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev 2009; 25:302 - 6; http://dx.doi.org/10.1002/dmrr.933; PMID: 19319985
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226 - 34; http://dx.doi.org/10.1038/nrd2804; PMID: 19247305
   PubMed Web of Science ®Google Scholar
• Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23:1283 - 8; http://dx.doi.org/10.1038/nbt1143; PMID: 16186811
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall’acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2009; 46:1750 - 5; http://dx.doi.org/10.1016/j.molimm.2009.01.026; PMID: 19250681
   PubMed Web of Science ®Google Scholar
• Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. Identity of the elusive IgM Fc receptor (FcmuR) in humans. J Exp Med 2009; 206:2779 - 93; http://dx.doi.org/10.1084/jem.20091107; PMID: 19858324
   PubMed Web of Science ®Google Scholar
• Chen K, Xu W, Wilson M, He B, Miller NW, Bengtén E, et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat Immunol 2009; 10:889 - 98; http://dx.doi.org/10.1038/ni.1748; PMID: 19561614
   PubMed Web of Science ®Google Scholar
• Jönsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, Khun H, et al. Human FcγRIIA induces anaphylactic and allergic reactions. Blood 2012; 119:2533 - 44; http://dx.doi.org/10.1182/blood-2011-07-367334; PMID: 22138510
   PubMed Web of Science ®Google Scholar
• Lu J, Ellsworth JL, Hamacher N, Oak SW, Sun PD. Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. J Biol Chem 2011; 286:40608 - 13; http://dx.doi.org/10.1074/jbc.M111.257550; PMID: 21965667
   PubMed Web of Science ®Google Scholar
• Ramsland PA, Farrugia W, Bradford TM, Sardjono CT, Esparon S, Trist HM, et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol 2011; 187:3208 - 17; http://dx.doi.org/10.4049/jimmunol.1101467; PMID: 21856937
   PubMed Web of Science ®Google Scholar
• Holdom MD, Davies AM, Nettleship JE, Bagby SC, Dhaliwal B, Girardi E, et al. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI. Nat Struct Mol Biol 2011; 18:571 - 6; http://dx.doi.org/10.1038/nsmb.2044; PMID: 21516097
   PubMed Web of Science ®Google Scholar
• Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 2011; 16:1071 - 80; http://dx.doi.org/10.1111/j.1365-2443.2011.01552.x; PMID: 22023369
   PubMed Web of Science ®Google Scholar
• Carroll-Portillo A, Spendier K, Pfeiffer J, Griffiths G, Li H, Lidke KA, et al. Formation of a mast cell synapse: Fc ε RI membrane dynamics upon binding mobile or immobilized ligands on surfaces. J Immunol 2010; 184:1328 - 38; http://dx.doi.org/10.4049/jimmunol.0903071; PMID: 20042583
   PubMed Web of Science ®Google Scholar
• Hubert P, Heitzmann A, Viel S, Nicolas A, Sastre-Garau X, Oppezzo P, et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res 2011; 71:5134 - 43; http://dx.doi.org/10.1158/0008-5472.CAN-10-4222; PMID: 21697279
   PubMed Web of Science ®Google Scholar
• Beekman JM, Bakema JE, van der Poel CE, van der Linden JA, van de Winkel JG, Leusen JH. Protein 4.1G binds to a unique motif within the Fc γ RI cytoplasmic tail. Mol Immunol 2008; 45:2069 - 75; http://dx.doi.org/10.1016/j.molimm.2007.10.024; PMID: 18023480
   PubMed Web of Science ®Google Scholar
• Gibson AW, Li X, Wu J, Baskin JG, Raman C, Edberg JC, et al. Serine phosphorylation of FcγRI cytoplasmic domain directs lipid raft localization and interaction with protein 4.1G. J Leukoc Biol 2012; 91:97 - 103; http://dx.doi.org/10.1189/jlb.0711368; PMID: 22003208
   PubMed Web of Science ®Google Scholar
• Bournazos S, Hart SP, Chamberlain LH, Glennie MJ, Dransfield I. Association of FcgammaRIIa (CD32a) with lipid rafts regulates ligand binding activity. J Immunol 2009; 182:8026 - 36; http://dx.doi.org/10.4049/jimmunol.0900107; PMID: 19494328
   PubMed Web of Science ®Google Scholar
• Bakema JE, Ganzevles SH, Fluitsma DM, Schilham MW, Beelen RH, Valerius T, et al. Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy. J Immunol 2011; 187:726 - 32; http://dx.doi.org/10.4049/jimmunol.1002581; PMID: 21653835
   PubMed Web of Science ®Google Scholar
• Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, et al. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol 2011; 186:3770 - 8; http://dx.doi.org/10.4049/jimmunol.1003082; PMID: 21317397
   PubMed Web of Science ®Google Scholar
• Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Kooten C, et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 2011; 186:3113 - 9; http://dx.doi.org/10.4049/jimmunol.1003189; PMID: 21257971
   PubMed Web of Science ®Google Scholar
• Bakema JE, van Egmond M. Immunoglobulin A: A next generation of therapeutic antibodies?. MAbs 2011; 3:352 - 61; http://dx.doi.org/10.4161/mabs.3.4.16092; PMID: 21691145
   PubMed Web of Science ®Google Scholar
• Woof JM, Russell MW. Structure and function relationships in IgA. Mucosal Immunol 2011; 4:590 - 7; http://dx.doi.org/10.1038/mi.2011.39; PMID: 21937984
   PubMed Web of Science ®Google Scholar
• Beyer T, Lohse S, Berger S, Peipp M, Valerius T, Dechant M. Serum-free production and purification of chimeric IgA antibodies. J Immunol Methods 2009; 346:26 - 37; http://dx.doi.org/10.1016/j.jim.2009.05.002; PMID: 19427867
   PubMed Web of Science ®Google Scholar
• Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, et al. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother 2011; http://dx.doi.org/10.1007/s00262-011-1162-8; PMID: 22139135
   PubMed Web of Science ®Google Scholar
• Call ME, Chou JJ. A view into the blind spot: solution NMR provides new insights into signal transduction across the lipid bilayer. Structure 2010; 18:1559 - 69; http://dx.doi.org/10.1016/j.str.2010.11.002; PMID: 21134635
   PubMed Web of Science ®Google Scholar
• Yahav T, Maimon T, Grossman E, Dahan I, Medalia O. Cryo-electron tomography: gaining insight into cellular processes by structural approaches. Curr Opin Struct Biol 2011; 21:670 - 7; http://dx.doi.org/10.1016/j.sbi.2011.07.004; PMID: 21813274
   PubMed Web of Science ®Google Scholar
• Spendier K, Lidke KA, Lidke DS, Thomas JL. Single-particle tracking of immunoglobulin E receptors (FcεRI) in micron-sized clusters and receptor patches. FEBS Lett 2012; 586:416 - 21; http://dx.doi.org/10.1016/j.febslet.2012.01.013; PMID: 22265688
   PubMed Web of Science ®Google Scholar
• Zarnitsyna VI, Zhu C. Adhesion frequency assay for in situ kinetics analysis of cross-junctional molecular interactions at the cell-cell interface. J Vis Exp 2011; e3519; PMID: 22083316
   PubMedGoogle Scholar
• Shashidharamurthy R, Zhang F, Amano A, Kamat A, Panchanathan R, Ezekwudo D, et al. Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A. J Immunol 2009; 183:8216 - 24; http://dx.doi.org/10.4049/jimmunol.0902550; PMID: 20007585
   PubMed Web of Science ®Google Scholar